Decreased Hepatic Breast Cancer Resistance Protein Expression and Function in Multidrug Resistance-Associated Protein 2-Deficient (TR−) Rats
- 24 November 2010
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 39 (3), 441-447
- https://doi.org/10.1124/dmd.110.035188
Abstract
Multidrug resistance-associated protein (Mrp) 2-deficient (TR−) Wistar rats have been used to elucidate the role of Mrp2 in drug disposition. Decreased breast cancer resistance protein (Bcrp) levels were reported in sandwich-cultured hepatocytes (SCH) from TR− rats compared with those from wild-type (WT) rats. This study was designed to characterize hepatic Bcrp expression and function in TR− rats, using nitrofurantoin and pitavastatin as substrates. Bcrp was knocked down by RNA interference in rat SCH. Antibody BXP53, but not BXP21, specifically detected Bcrp knockdown in SCH. Bcrp protein levels were decreased markedly in TR− but not Mrp2-deficient Sprague-Dawley [Eisai hyperbilirubinemic rats (EHBR)] rats. Bcrp mRNA levels were decreased significantly in TR− livers as determined by TaqMan real-time reverse transcriptase-polymerase chain reaction. Biliary excretion of nitrofurantoin, a specific Bcrp substrate, was decreased significantly in SCH and isolated perfused livers from TR− rats compared with those from WT controls, indicating that hepatic Bcrp function is decreased in TR− rats. In Bcrp knockdown SCH, the biliary excretion index and in vitro biliary clearance of pitavastatin were decreased significantly to ∼58 and ∼52% of control, respectively, indicating that Bcrp plays a role in pitavastatin biliary excretion. Pitavastatin biliary excretion was decreased significantly in perfused livers from TR− compared with those from WT rats. In conclusion, expression and function of hepatic Bcrp are decreased significantly in TR− rats. The potential role of both Bcrp and Mrp2 should be considered when data generated in TR− rats are interpreted. TR− and EHBR rats in combination may be useful in differentiating the role of Mrp2 and Bcrp in drug/metabolite disposition.Keywords
This publication has 45 references indexed in Scilit:
- Hepatic Metabolism and Biliary Excretion of Valerenic Acid in Isolated Perfused Rat Livers: Role of Mrp2 (Abcc2)Journal of Pharmaceutical Sciences, 2009
- MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer CellsMolecular Pharmacology, 2009
- Knocking Down Breast Cancer Resistance Protein (Bcrp) by Adenoviral Vector-Mediated RNA Interference (RNAi) in Sandwich-Cultured Rat Hepatocytes: A Novel Tool To Assess the Contribution of Bcrp to Drug Biliary ExcretionMolecular Pharmaceutics, 2008
- Apparent Differences in Mechanisms of Harmol Sulfate Biliary Excretion in Mice and RatsDrug Metabolism and Disposition, 2008
- In Vitro Biliary Clearance of Angiotensin II Receptor Blockers and 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors in Sandwich-Cultured Rat Hepatocytes: Comparison with in Vivo Biliary ClearanceThe Journal of pharmacology and experimental therapeutics, 2008
- Impact of Basolateral Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 on the Hepatobiliary Disposition of Fexofenadine in Perfused Mouse LiversDrug Metabolism and Disposition, 2008
- Identification and Functional Assessment ofBCRPPolymorphisms in a Korean PopulationDrug Metabolism and Disposition, 2007
- ALTERED HEPATOBILIARY DISPOSITION OF 5 (AND 6)-CARBOXY-2′,7′-DICHLOROFLUORESCEIN INAbcg2(Bcrp1) ANDAbcc2(Mrp2) KNOCKOUT MICEDrug Metabolism and Disposition, 2006
- Effect of ABCG2 genotype on the oral vioavailability of topotecanCancer Biology & Therapy, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001